A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with endometrial cancer lose weight.

Recruiting now. Registry record last updated April 28, 2026.

Who can join: Adults 18+, women only, have endometrial cancer, BMI 30+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 1Sponsor UNC Lineberger Comprehensive Cancer CenterDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 20

What this study is for

Primary condition: Endometrial Cancer. Also studied in: Obesity.

Full scientific study title: Tirzepatide in Obesity-Driven Endometrial Cancer.

Who can join

Age18 and upSexFemaleBMI30 or higher

Adults 18+, women only, have endometrial cancer, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Current diagnosis of endometrioid histology cancer and scheduled to undergo hysterectomy and staging.
Agree to comply with all required study assessments and visits including internet capabilities.
Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
Age ≥ 18 at the time of consent.
Body mass index of ≥30 kg/m2.

Key exclusion criteria

Active infection requiring systemic therapy.
Subject is pregnant or breast feeding.
Taking any prescription medications or other drugs that may influence metabolism per discretion of investigator.
Taking a central nervous system stimulant.
Current psychological conditions that would be incompatible with participation in this study, as determined by investigator.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

North Carolina1 site

Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Victoria Bae-Jump, M.D., PhD919-966-5996victoria_baejump@med.unc.edu

Follow this trial

We email you if NCT07065552 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: April 27, 2026. Expected completion: July 2028. Last updated on ClinicalTrials.gov: April 28, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.